

07.00	Registration						
08.30 - 10.30	Opening Ceremony & Reducing Harms for People Who Use Drugs Room: Lomond Auditorium Chairs: John Dillon, University of Dundee, UK & Rachel Halford, Hep C Trust, UK						
08.30 - 08.40	Welcome to the Conference John Dillon, University of Dundee, UK						
08.40 - 08.45	Government Welcome Maree Todd, Minister for Public Health, Women's Health and Sport, Scotland						
08.45 - 08.50	Community Opening Jason Wallace, Scottish Drugs Forum, UK						
08.50 - 09.00	Awards						
09.00 - 09.20	Evidence-based approaches for reducing drug-related deaths – What interventions work and what does the future hold? Andrew McAuley, Public Health Scotland/Glasgow Caledonian University, Scotland						
09.20 - 09.40	How can we overcome legal barriers to reduce criminalisation and improve the health of people who use drugs? Niamh Eastwood, Release, UK						
09.40 - 10.00	Questions & Discussion						
10.00 - 10.15	The impact of disruptions to services for people who inject drugs in Ukraine: Modelling the potential impact of Russia's invasion Jack Stone, University of Bristol, UK						
10.15 - 10.30	Implications of using current mechanisms of Opioid Agonist Treatment (OAT) provision to access 'Safer Supply' in British Columbia Marion Selfridge, Canadian Institute for Substance Use Research, Canada						
10.30 - 11.00	Coffee Break						
11.00 - 13.00	Plenary Session B: Community Perspectives on Strategies to Reduce Harms Amongst People Who Use Drugs Room: Lomond Auditorium Chair: Jason Grebely, The Kirby Institute, UNSW Sydney, Australia						
11.00 - 11.45	What fresh hell is this? Benzo dope and tranq dope Chair: Garth Mullins, Producer and host of crackdown podcast Panellists: Matt Bonn, Canadian Association of People who Use Drugs, Canada; Stone Crawford, Harm Reduction Victoria, Australia; Louise Vincent, NC Survivor's Union, USA & Jason Wallace, Scottish Drugs Forum, UK						
11.45 - 12.15	Connecting with Care: person-centered models of care for HCV Conor Ashleigh, Australia & John Dillon, University of Dundee, UK, Angela McBride, South African Network of People who Use Drugs (SANPUD), South Africa & Koketso Mokubane, South African Network of People who Use Drugs (SANPUD), South Africa						
12.15 - 13.00	Opioid agonist treatment (OAT): why choice matters Moderator: Conor Ashleigh, Australia Panellists: Sione Crawford, Harm Reduction Victoria, Australia; Jane Dicka, Harm Reduction Victoria, Australia						
13.00 - 14.15	Lunch & Poster Viewing						
13.00 - 13.45	My Choice Photo Exhibition Tour						
13.15 - 14.00	Industry Sponsored Symposia: People-Centred HCV Care: Simply Delivered Room: Lomond Auditorium						
13.15 - 13.20	Welcome and Introduction Ashley Brown, Imperial College London, UK						
13.20 - 13.30	Let's Tick HCV Off the List Ashley Brown, Imperial College London, UK						
13.30 - 13.38	My HCV Journey: A Peer's Perspective Ashley Brown, Imperial College London, UK; Lesley Gallagher, SIDCN (Saskatchewan Infectious Disease Care Network), Canada						
13.38 - 13.53	Simply Delivering HCV Cure Lesley Gallagher, SIDCN (Saskatchewan Infectious Disease Care Network), Canada						
13.53 - 13.58	Audience Q&A						
13.58 - 14.00	Close Ashley Brown, Imperial College London, UK						
14.15 - 15.30	Session C Oral Abstract Session: Reducing harms that may relate to drug use Room: Lomond Auditorium Chairs: Catriona Matheson, University of Stirling, UK & Alexander Walley, Boston University School of Medicine, USA	14.15 - 15.25	Session D Oral Abstract Session: Drug use trends and overdose Room: Alsh (A) Chairs: Chrianna Bharat, National Drug and Alcohol Research Centre, Australia & Jack Stone, University of Bristol, UK	14.15 - 15.25	Session E Oral Abstract Session: Infectious diseases Room: Boisdale (B) Chairs: Matthew Akiyama, Albert Einstein College of Medicine, USA & Monica Desai, UK Health Security Agency, UK	14.15 - 15.25	Session F Oral Abstract Session: COVID-19 Room: Dochart (D) Chairs: Josie Smith, Public Health Wales, UK & Ryan Westergaard, Division of Infectious Disease, UW Madison School of Medicine and Public Health, USA
14.15 - 14.30	'Safer Supply (SS) and HCV micro-elimination during COVID 19 - Prescribing novel opioid and stimulant alternatives to toxic illicit drug supply in Victoria, British Columbia Marion Selfridge, Cool AID Community Health Centre, Canada	14.15 - 14.30	The impact of opioid agonist treatment on fatal and non-fatal drug overdose among people with a history of opioid dependence in NSW, Australia, 2001-2018: Findings from the OATS retrospective linkage study Nicola Jones, National Drug And Alcohol Research Centre, Australia	14.15 - 14.30	Social and structural determinants of injecting-related bacterial and fungal infections among people who inject drugs: qualitative systematic review and thematic synthesis Thomas Brothers, Dalhousie University & University College London, Canada	14.15 - 14.30	SARS-CoV-2 vaccine uptake and risks of severe COVID-19 disease among people prescribed opioid agonist therapy in Scotland Alan Yeung, Glasgow Caledonian University, UK
14.30 - 14.45	The global coverage of interventions to prevent and manage drug-related harms among people who inject drugs: A multi-stage systematic review of the evidence Louisa Degenhardt, National Drug and Alcohol Research Centre UNSW, Australia	14.30 - 14.45	Barriers to management of opioid withdrawal in hospitals in England: a document analysis of hospital policies Magdalena Harris, London School Of Hygiene And Tropical Medicine, UK	14.30 - 14.45	The association between access to opioid substitution therapy and HIV incidence among people who inject drugs (PWID) in Kachin, Myanmar, 2008-2020 Peter Vickerman, University of Bristol, UK	14.30 - 14.45	Co-constructing a community-based telemedicine program to meet the needs of vulnerable people with opioid use disorder during COVID-19 Stine Hoj, University of Montreal Hospital Research Centre (CRCHUM), Canada
14.45 - 15.00	A novel contingency management intervention in the context of a syndemic of drug-related harms in Glasgow: First year of the 'WAND' initiative Shanley Smith, Glasgow Caledonian University / Public Health Scotland, UK	14.45 - 15.00	Age and chronic disease-specific associations between opioid agonist treatment and opioid overdose death by age and chronic disease status: Cohort study using linked administrative health data in New South Wales, Australia, 2001-2018 Sarah Larney, Université De Montréal, Canada	14.45 - 15.00	Models of good practice interventions to enhance the infectious disease care cascade among people who inject drugs: A qualitative study Tanja Schwarz, Austrian National Public Health Institute (GOEG), Austria	14.45 - 15.00	"We weren't just breaking the law by taking drugs, we were breaking the law by simply being together": a qualitative study of people engaged in opioid agonist treatment as a counterpublic during the COVID-19 pandemic in Australia Anna Conway, Kirby Institute, UNSW, Australia
15.00 - 15.05	The safety and utility of benzodiazepine (bzd) prescribing among people receiving OAT in Scotland: analysis of a national dataset over 11 years Catriona Matheson, University of Stirling, UK	15.00 - 15.05	Binge drug injection among people who inject drugs in Montreal: characterizing the substances and social contexts involved to inform prevention efforts Nanor Minoan, CRCHUM / Université de Montréal, Canada	15.00 - 15.05	Major barriers and facilitators to transitions of care for patients hospitalized with infectious complications of opioid use disorder: A multi-site, qualitative analysis of expert stakeholders Sarah Kattakuzhy, Institute of Human Virology at the University of Maryland, USA	15.00 - 15.05	Factors associated with SARS-COV-2 infection and severe COVID-19 disease among individuals prescribed opioid agonist treatment in Scotland Megan Gancy, Glasgow Caledonian University/public Health Scotland, UK
15.05 - 15.10	"Why would we not want to keep everybody safe?" Views of family members of people who use drugs and strategic decisions makers on the implementation of drug consumption rooms in Scotland Tessa Parkes, University of Stirling, UK	15.05 - 15.10	Increased risk of non-fatal overdose associated with NPS-type ['street'] benzodiazepine use in Scotland, UK Andrew McAuley, Glasgow Caledonian University, UK	15.05 - 15.10	High levels of HCV transmission and a new outbreak of HIV infection during the COVID-19 pandemic among people who inject drugs in Thessaloniki, Greece Sotirios Roussos, National and Kapodistrian University of Athens, Greece	15.05 - 15.10	Impacts of COVID-19 on people who use and inject drugs in Australia Shelley Walker, Burnet Insitute, Australia
15.10 - 15.15	A qualitative exploration of three hypothetical models of drug checking service delivery in a Scottish context Danilo Falzon, University of Stirling, UK	15.10 - 15.15	Shifts in common causes of death among adults with opioid use disorders - A retrospective Swiss opioid agonist treatment cohort study over 22 years Philip Bruggmann, Arud, Centre for Addiction Medicine, Switzerland	15.10 - 15.15	Restore: A peer facilitated model for substance use disorder care integration into outpatient infectious disease care Oluwaseun Falade-Nwulia, Johns Hopkins University School of Medicine, USA	15.10 - 15.15	Modified map in COVID quarantine Bronwyn Gordon, Drug & Alcohol Services SA, Australia
15.15 - 15.20	Knowledge and diffusion of take-home naloxone among people who use opioids in France Salim Mezaache, Marseille University Hospitals, France	15.15 - 15.20	Exploring the lived experience of drug-induced overdose through peer-led interviews. Teresa Flynn, Hillcrest Futures, UK	15.15 - 15.20	Same-day testing and treatment of sexually transmitted infections among female sex workers who use drugs using nucleic acid amplification testing at a point-of-care mobile unit Jorge Valencia, Hospital Universitario Infanta Leonor, Spain	15.15 - 15.20	Prolonged Dam-Take-Home in times of COVID-19: Harm reduction or increase? Franciska Brezan, Arud Centres for Addiction Medicine, Switzerland
15.20 - 15.25	Economic evaluation of syringe vending machines in Tbilisi, Georgia Josephine Walker, University Of Bristol, UK	15.20 - 15.25	Preliminary results from a randomized controlled trial of an integrated care model of infectious disease management and long-acting injectable buprenorphine for patients hospitalized with infections and opioid use disorder Sandra Springer, Yale School of Medicine, USA	15.20 - 15.25	An evaluation of the health impact of injecting drug use on acute secondary care services: The east of Scotland experience Caitlin Macleod, NHS Tayside, UK	15.20 - 15.25	Evaluation of an emergency safe supply drugs and managed alcohol program in COVID-19 isolation hotel shelters for people experiencing homelessness Thomas Brothers, Dalhousie University & University College London, Canada
15.30 - 16.15	Coffee Break & Poster Tour						
15.40 - 16.05	Poster Tour 01: Key Populations Chair: Benjamin Eckhardt, NYU School of Medicine/Bellevue Hospital, USA			15.40 - 16.05	Poster Tour 02: Data, Data, Data Chair: Anna Conway, The Kirby Institute, UNSW Sydney, Australia		
15.40 - 15.45	The Hepatitis Engagement Program (HEP): Towards the elimination of Hepatitis C vertical transmission in New Brunswick, Canada Katie Harland, Centre For Research, Education, And Clinical Care Of At-risk Populations, Canada			15.40 - 15.45	Phylogenetic transmission clusters of Hepatitis C virus among people who use drugs who access harm reduction services in three South African cities, 2016 – 2017 Nkosenhle Ndlovu, University of the Witwatersrand, South Africa		
15.45 - 15.50	Reducing the Time-To-Treatment for patients with HCV in English remand prisons Arran Ludlow Rhodes, Practice Plus Group, UK			15.45 - 15.50	Drug dependence and Hepatitis C RNA testing and treatment in the era of direct-acting antiviral therapy among people with a Hepatitis C notification in New South Wales, Australia Mohammad Tahir Yousafzai, The Kirby Institute, UNSW Sydney, Australia		
15.50 - 15.55	Impact of HCV testing and treatment services on HCV transmission among men who have sex with men and inject drugs in San Francisco: A modelling analysis Adelina Arterio, University of Bristol, UK			15.50 - 15.55	Development and validation of a global model to optimize HIV resource allocation among people who inject drugs: The intrepid model Natasha Martin, University of California San Diego, USA		
15.55 - 16.00	Higher incidence of HCV re-infection among treatment experienced people who inject drugs in Tayside, Scotland. Christopher Byrne, University of Dundee, UK			15.55 - 16.00	The benefits of a regional collaborative drug related death review and surveillance system: Insights from implementation in the north west of England Howard Reed, Public Health Institute, Liverpool John Moores University, UK		
16.00 - 16.05	Modelling the impact of the care cascade amongst young people who inject drugs in San Francisco Hannah Fraser, University Of Bristol, UK						

16.15 - 17.45	<p>Session G: Drug treatment: The need for patient choice Room: Lomond Auditorium</p> <p>Chairs: Suzanne Nielsen, Monash Addiction Research Centre, Monash University, Australia & Christopher Fraser, Cool Aid Community Health, Canada</p>	16.15 - 17.45	<p>Session H: Viral Hepatitis and HIV among people who use drugs and people in prison settings : updated WHO guidance for evidence- based and person-centred care and lessons learned from countries Room: Alsh (A)</p> <p>Chairs: Natasha Martin, University of California, San Diego, USA & Philip Bruggmann, Arud, Centre for Addiction Medicine, Switzerland</p>	16.15 - 17.45	<p>Session I: Infectious diseases beyond Hepatitis C Room: Boisdale (B)</p> <p>Chairs: Oluwaseun Falade-Nwulia, Johns Hopkins University School of Medicine, USA & Andrew Scheibe, TB HIV Care, South Africa</p>	16.15 - 17.45	<p>Session J: Four nations, one aim: UK Delivery of HCV Elimination Room: Dochart (D)</p> <p>Chair: Mark Gillyon-Powell, Head of Programme - HCV Elimination, NHS England and NHS Improvement, UK</p>
16.15 - 16.35	<p>Treatment for opioid and stimulant dependence: Current options and future directions Thilo Beck, Arud Centres for Addiction Medicine, Switzerland</p>	16.15 - 16.18	<p>Framing the session Natasha Martin, University of California, San Diego, USA & Philip Bruggmann, Arud, Centre for Addiction Medicine, Switzerland</p>	16.15 - 16.35	<p>Skin and soft tissue infections – Personal reflections and the need for transformative justice Danielle Russell, Arizona State University, USA</p>	16.15 - 16.20	<p>Introduction to Four nations, one aim: UK Delivery of HCV Elimination Mark Gillyon-Powell, Head of Programme - HCV Elimination, NHS England and NHS Improvement, England</p>
16.35 - 16.55	<p>Opioid Pharmacotherapy and Choice: A Social Science Perspective Joanne Neale, Kings College London, UK</p>	16.18 - 16.33	<p>New guidance from WHO: overview (KP, HCVST, HCV service delivery, validation of elimination) Niklas Luhmann, WHO, Switzerland</p>	16.35 - 16.55	<p>Epidemiology, natural history and treatment for hepatitis B and D infections: Implications for people who inject drugs Heiner Wedemeyer, Hannover Medical School, Germany</p>	16.20 - 16.35	<p>Scotland John Dillon, University of Dundee, UK</p>
16.55 - 17.15	<p>Time for a new normal - empowerment through drug treatment Mat Southwell, European Network of People who use Drugs, UK</p>	16.33 - 16.41	<p>Experiences with HCV retesting and immediate treatment in harm reduction programs in Australia Margaret Hellard, Burnet Institute, Australia</p>	16.55 - 17.15	<p>Everything you need to know about Tuberculosis in 20 minutes Al Story, University College Hospitals Nhs Foundation Trust, UK</p>	16.35 - 16.50	<p>Northern Ireland Neil McDougall, Susan Semple & Gemma Wasson, Belfast Health and Social Care Trust, Ireland</p>
17.15 - 17.45	<p>Questions & Discussion</p>	16.41 - 16.49	<p>Scaling-up prisoners' access to integrated HIV, HCV and OAT services in Ukraine (PATH) Svitlana Leontieva; PATH, Ukraine</p>	17.15 - 17.45	<p>Questions & Discussion</p>	16.50 - 17.05	<p>England Mark Gillyon-Powell, Prof Graham Foster & Georgia Threadgold, NHS England</p>
		16.49 - 16.54	<p>Questions & Discussion Natasha Martin, University of California, San Diego, USA & Philip Bruggmann, Arud Centre for Addiction Medicine, Switzerland</p>			17.05 - 17.20	<p>Wales Brendan Healy, Public Health Wales, Wales</p>
		16.54 - 17.02	<p>HCV incidence: WHO elimination targets and the case of Georgia Davit Baliashvili, The Taskforce for Global Health, Georgia</p>			17.20 - 17.40	<p>Discussion</p>
		17.02 - 17.10	<p>Improving harm reduction services in the framework of HCV elimination in Egypt Mohamed Hassany, Ministry of Health, Egypt</p>			17.40 - 17.45	<p>Closing Words Mark Gillyon-Powell, Head of Programme - HCV Elimination, NHS England and NHS Improvement, England</p>
		17.10 - 17.15	<p>Questions & Discussion Natasha Martin, University of California, San Diego, USA & Philip Bruggmann, Arud, Centre for Addiction Medicine, Switzerland</p>				
		17.15 - 17.40	<p>What will it need to achieve HCV elimination among PWID and in prison settings? Monica Ciupagea, UNODC, Austria; Kanudeep Kaur, FIND, Switzerland; Karin Timmermanns, Unitaid, Switzerland; Annie Madden, International Network of People Who Use Drugs (INPUD), Australia; Julia Sheehan, Hep C Trust, UK; Minn Thit Aung, Medecins Du Monde (France), Burma</p>				
		17.40 - 17.45	<p>Closing Remarks Natasha Martin, University of California, San Diego, USA & Philip Bruggmann, Arud, Centre for Addiction Medicine, Switzerland</p>				
17.45 - 19.00	<p>Civic reception hosted by The Rt Hon The Lord Provost of Glasgow & Poster Viewing</p>						

07.30	Registration						
08.00 - 08.45	Industry Sponsored Symposium: Point of Care HCV RNA diagnostics Improve Test and Treat Pathways Room: Lomond Auditorium Chair: Jason Grebely, The Kirby Institute, UNSW Sydney, Australia						
8.00 - 8.10	Achieving national scale-up of point-of-care HCV testing Jason Grebely, The Kirby Institute, UNSW Sydney, Australia						
8.10 - 8.20	On the Road with Lucy! Mim O'Flynn, Kombi Clinic, Australia						
8.20 - 8.30	Point of Care Testing on Two Wheels in Brussels Lise Meunier, Réseau Hépatite C Bruxelles asbl, Belgium						
8.30 - 8.40	Engaging Marginalised Communities Danny Morris, Hep C Trust, UK						
8.40 - 8.45	Q & A						
09.00 - 10.45	Session K: Elimination of Hepatitis C infection: Where are we now and what is possible? Room: Lomond Auditorium Chairs: Niklas Luhmann, World Health Organization, Switzerland & Margaret Hellard, Burnet Institute, Australia						
09.00 - 09.20	HCV elimination among people who inject drugs – Where are we now and where to from here? Natasha Martin, University of California, San Diego, USA						
09.20 - 09.30	Real-world examples of success in achieving HCV elimination among people who inject drugs: Scotland John Dillon, University of Dundee, UK						
09.30 - 09.40	Real-world examples of success in achieving HCV elimination among people who inject drugs: Iceland Sigurdur Olafsson, Landspítali University Hospital, Iceland						
09.40 - 09.50	Real-world examples of success in achieving HCV elimination among people who inject drugs: Georgia Ketevan Stvilia, National Center for Disease Control, Georgia						
09.55 - 10.15	Questions & Discussion						
10.15 - 10.30	Changes in self-reported quality of life associated with successful DAA Hepatitis C treatment in people who use drugs Scott McDonald, Glasgow Caledonian University, UK						
10.30 - 10.45	Opportunistic treatment of Hepatitis C infection: A randomized controlled trial of immediate treatment initiation among hospitalized people who inject drugs (Opportuni-C) Håvard Midgard, Akershus University Hospital, Norway						
10.45 - 11.15	Coffee Break						
11.15 - 12.15	Prevention and control of HCV and HIV among people who inject drugs in 2022 and beyond: new evidence and key recommendations within the updated public health guidance ECDC/EMCDDA Room: Lomond Auditorium Chairs: Otilia Mardh, ECDC, Sweden and Thomas Seyler, EMCDDA, Portugal	11.15 - 12.15	Informing elimination strategies and harm reduction policies through bio-behavioural surveys among people who inject drugs Room: Alsh (A) Chairs: Vivian Hope, Liverpool John Moores University, UK & Sharon Hutchinson, Public Health Scotland & Glasgow Caledonian University, UK	11.15 - 12.15	The Nursing Perspective - overdose, safe supply, and hepatitis C Room: Boisdale (B) Chairs: Jan Tait, Ninewells Hospital and Medical School, UK & Pauline Dundas, NHS Grampian, UK	11.15 - 12.15	Peer Involvement in Research Room: Dochart (D) Chair: Matt Smith, Glasgow Caledonian University, UK
11.15 - 11.25	Summary of the updated guidance Otilia Mardh, ECDC, Sweden, and Thomas Seyler, EMCDDA, Portugal	11.15 - 11.25	Welcome, introductions and background context Vivian Hope, Liverpool John Moores University, UK and Sharon Hutchinson, Public Health Scotland & Glasgow Caledonian University, UK	11.15 - 11.20	Welcome & introductions Jan Tait, Ninewells Hospital and Medical School, UK Pauline Dundas, NHS Grampian, UK	11.15 - 11.25	Our experiences- findings from a peer research evaluation study Matt Smith, Glasgow Caledonian University, UK
11.25 - 11.35	The evidence base: Effectiveness of drug treatment, NSP and DCRs for the prevention of HCV, HIV and injecting risk behaviour among PWID Norah Palmateer, Public Health Scotland, UK	11.25 - 11.35	Using bio-behavioural surveys to inform and evaluate elimination strategies Monica Desai, UK Health Security Agency, UK	11.20 - 11.35	Drug related deaths Mary Munro, Scottish Ambulance Service, UK	11.25 - 12.00	Workshops facilitated by peer researchers: Sharing experiences to formulate key recommendations with delegate Jason Wallace, Scottish Drugs Forum, UK; Lawrie Elliott, Glasgow Caledonian University, UK; Gaby Vojt, Glasgow Caledonian University; Matt Smith, Glasgow Caledonian University, UK
11.35 - 11.45	The evidence base: Review of mathematical modelling studies of OST and NSP for preventing HCV transmission Lara Gordon, University of Bristol, UK	11.35 - 11.45	Using bio-behavioural surveys to inform and evaluate harm reduction policies Andrew McAuley, Public Health Scotland/Glasgow Caledonian University, Scotland	11.35 - 11.50	Safe supply Emmet O'Reilly, South Riverdale Community Health Centre, Canada	12.00 - 12.15	Summing up Matt Smith, Glasgow Caledonian University, UK
11.45 - 11.55	The evidence base: Improving the cascade of care for HCV among PWID Tanja Schwartz, Addiction Competence Centre, Austrian National Public Health Institute, Austria	11.45 - 11.55	The role of bio-behavioural surveys in research Joseph Cox, Public Health Agency of Canada, Canada	11.50 - 12.10	Panel Discussion - Drug related deaths, safe supply and HCV		
11.55 - 12.10	Panel Discussion: From guidance recommendations to practice	11.55 - 12.15	Panel discussion and closing remarks Vivian Hope, Liverpool John Moores University, UK and Sharon Hutchinson, Glasgow Caledonian University, Scotland	12.10 - 12.15	Closing Remarks Jan Tait, Ninewells Hospital and Medical School, UK Pauline Dundas, NHS Grampian, UK		
12.10 - 12.15	Closing Remarks						
12.15 - 14.00	Lunch and Poster Viewing						
12.45 - 13.45	Industry Sponsored Symposium: Right here, right now: Strategies to enhance the HCV care cascade Room: Lomond Auditorium						
12.45 - 12.50	HCV care right now – where are we at? Jason Grebely, The Kirby Institute, UNSW Sydney, Australia						
12.50 - 13.03	The first step to treating now – how can we simplify testing to identify all HCV-infected patients? Jason Grebely, The Kirby Institute, UNSW Sydney, Australia						
13.03 - 13.16	How can we empower patients to engage with care? Rachel Halford, The Hepatitis C Trust, UK; Mim O'Flynn, Kombi Clinic, Australia						
13.16 - 13.29	Are we doing enough to manage the patients in front of us? John Dillon, University of Dundee, UK						
13.29 - 13.45	Panel discussion and Q&A Jason Grebely, The Kirby Institute, UNSW Sydney, Australia; Rachel Halford, The Hepatitis C Trust, UK; Mim O'Flynn, Kombi Clinic, Australia; John Dillon, University of Dundee, UK						
14.00 - 15.00	Session L: Oral Abstract Session: Strategies to enhance HCV testing Room: Lomond Auditorium Chairs: Melisa Dickie, CATIE, Canada & Andrew Radley, NHS Tayside, UK	14.00 - 15.05	Session M: Oral Abstract Session: Interventions to enhance HCV testing and treatment Room: Alsh (A) Chairs: Stephen Barclay, Glasgow Royal Infirmary, UK & Nadine Kronfli, McGill University, Canada	14.00 - 15.15	Session N: Oral Abstract Session: Prisons Room: Boisdale (B) Chairs: Yumi Sheehan, Australian National Prisons Hepatitis Network / The Kirby Institute UNSW Sydney, Australia & Matthew Akiyama, Albert Einstein College of Medicine / Montefiore Medical Centre, New York, USA	14.00 - 15.00	Session O: Oral Abstract Session: Striving towards HCV elimination Room: Dochart (D) Chairs: Sofia Bartlett, BC Centre for Disease Control, Clinical Prevention Services, Canada & David Perlman, Icahn School of Medicine at Mount Sinai, USA
14.00 - 14.15	A novel Hepatitis C intervention in Denmark to test and treat people who inject drugs Anne Overhus, Odense University Hospital, Denmark	14.00 - 14.15	Recruitment and treatment of social-injecting networks in the treatment and prevention study: A real-world social network design community-based trial of direct-acting antivirals for Hepatitis C among people who inject drugs Brendan Harney, Burnet Institute, Australia	14.00 - 14.15	Comprehensive HCV service delivery model for achieving micro-elimination of Hepatitis C among the incarcerated population of Haryana and Chandigarh, India Kanudeep Kaur, FIND, India	14.00 - 14.15	Evaluating the impact of direct-acting anti-viral therapy on Hepatitis C Viraemia among people who inject drugs Pantelis Samartsidis, University of Cambridge, UK
14.15 - 14.30	Two randomized controlled trials to measure the impact of HCV self-testing in key populations in Georgia and Malaysia Sonjelle Shilton, FIND, Switzerland	14.15 - 14.30	Innovative community-based strategy to eliminate HCV among people who inject drugs in Vietnam Nicolas Nagot, University of Montpellier, France	14.15 - 14.30	Micro-eliminating HCV in 8 diverse prisons that serve a general population of 3.7 million in the Yorkshire region of England. Nichola Royal, Practice Plus Group Ltd, UK	14.15 - 14.30	Changing Trends in Hepatitis C Reinfection Rates Following the Scale-Up of Direct-Acting Antivirals Among People Who Inject Drugs in Scotland Norah Palmateer, Glasgow Caledonian University, UK
14.30 - 14.45	Implementation of dried blood spot testing for HIV and Hepatitis C: The NSW DBS pilot study: A client-centred alternative to traditional health care Anna Conway, The Kirby Institute, UNSW Sydney, Australia	14.30 - 14.45	Understanding attitudes and concerns regarding the use of molecular cluster detection as a Hepatitis C elimination strategy: A qualitative study of persons who inject drugs Matthew Lambert, University of Wisconsin - Madison School of Medicine and Public Health, USA	14.30 - 14.45	Hepatitis C micro-elimination program in prisons across Greece: "Access4All in Greek Prisons" George Kalamitsis, Hellenic Liver Patients Association "Prometheus", Greece	14.30 - 14.45	Excess mortality risk among Hepatitis C patients after being "cured" in the interferon-free era: Results from three population-based cohorts Victoria Hamill, Glasgow Caledonian University, UK
14.45 - 14.50	HCV RNA Point-of-Care testing to measure HCV prevalence and incidence among service users of an integrated supervised consumption service in Toronto, Canada Zoë Greenwald, University of Toronto, Canada	14.45 - 14.50	Interventions to improve HCV care for people who inject drugs: A systematic review and meta-analysis Evan Cunningham, Kirby Institute, Australia	14.45 - 15.00	Trust and service engagement among people who inject drugs post-release Lise Lafferty, UNSW Sydney, Australia	14.45 - 14.50	"Treated like a Human Being": Perspectives of people who inject drugs attending low-threshold HCV treatment at a syringe service program in New York City. Shashi Kapadia, Weill Cornell Medicine, USA
14.50 - 14.55	Acceptability, appropriateness, and feasibility of an on-site HCV "Test and Treat" strategy at opioid treatment programs in North America Oluwaseun Falade-Nwulia, Johns Hopkins University School Of Medicine, USA	14.50 - 14.55	Factors associated with stigma, discrimination, and negative health care treatment among people who inject drugs: The ETHOS Engage Study Timothy Broady, Centre For Social Research In Health, Unsw, Australia	15.00 - 15.05	Barriers and facilitators to implementing Point-Of-Care RNA testing for Hepatitis C virus in a Scottish prison health centre. Christopher Byrne, University Of Dundee, UK	14.50 - 14.55	Characterizing the Hepatitis C virus cascade of care for First Nations individuals in Ontario, Canada Andrew Mendlowitz, Toronto Centre for Liver Disease, Canada
14.55 - 15.00	Peer and nursing-led outreach combined with Point-of-Care HCV testing to decentralise HCV care and enhance HCV treatment among people who use drugs, people who experience homelessness, and migrants: The Reach U Project Cristiana Merendeiro, CRESCECER - Community Intervention Association, Portugal	14.55 - 15.00	The role and importance of community-led values & preferences research in developing models of care for people who use drugs Annie Madden, International Network Of People Who Use Drugs (INPUD), Australia	15.05 - 15.10	Identifying barriers and enablers to opt-out Hepatitis C virus screening in provincial prisons in Quebec, Canada: A qualitative study with correctional stakeholders using the consolidated framework for implementation research Guillaume Fontaine, Centre for Implementation Research, Clinical Epidemiology Program, Ottawa Hospital Research Institute, Canada	14.55 - 15.00	Sustained reduction in active HCV infection in people seeking addiction treatment at the National Center of Addiction Medicine (Vogur Hospital) in Iceland Ragnheidur Fridriksdottir, National Center Of Addicition Medicine - SAA, Iceland
		15.00 - 15.05	Experiences of peer educators in managing people injecting drugs in the communities Regina Maitshufi, National Department Of Health, South Africa	15.10 - 15.15	Curing the "Hard to Reach" Rachael Bryett, Hepatitis Queensland, Australia		
15.00 - 15.45	Coffee Break						

15:45 - 17:15	<p>Session P: What's next in efforts to achieve and maintain HCV elimination among PWID Room: Lomond Auditorium</p> <p>Chairs: Erika Castro, Private Practice - HepC Virtual Clinic, Switzerland & Sigurdur Olafsson, Landspítali University Hospital, Iceland</p>	15:45 - 17:15	<p>Session Q: Interventions to reduce drug-related harms Room: Alsh (A)</p> <p>Chairs: Sione Crawford, Harm Reduction Victoria, Australia & Louise Hansford, Inclusion, UK</p>	15:45 - 17:15	<p>Session R: Moving forward towards broader implementation of "Safer Supply" Room: Boisdale (B)</p> <p>Chairs: Marion Selfridge, Cool Aid Community Health Centre, Canada & Anne-Sophie Thommeret-Carrière, Université de Montréal, Canada</p>	15:45 - 17:15	<p>Session S: Tips for getting your research published Room: Dochart (D)</p> <p>Chairs: Christopher Byrne, University of Dundee, UK; Shashi Kapadia, Weill Cornell Medicine, USA & Shelley Walker, Burnet Institute, Australia</p>
15:45 - 16:05	<p>Latest developments on rapid tests for HCV Sonjelle Shilton, FIND, Switzerland</p>	15:45 - 16:05	<p>Drug Consumption Rooms Ann Livingston, Nanaimo and Area Network of Drug Users, Canada</p>	15:45 - 16:05	<p>Deployment of safer supply in Canada Dr Andrea Sereda, London InterCommunity Health Centre, Canada & Alexandra Holtom, Canadian Association of People Who Use Drugs (CAPUD), Canada</p>	15:45 - 17:15	<p>Panel Discussion Jason Grebely, The Kirby Institute, UNSW, Sydney, Australia; Matt Hickman, University of Bristol, UK; Joanne Neale, Kings College London, UK; Alison Ritter, Social Policy Research Centre, Australia</p>
16:05 - 16:25	<p>Novel approaches to facilitate rapid scale-up of HCV treatment Graham Foster, Queen Mary University of London, UK</p>	16:05 - 16:25	<p>Overdose Prevention Louise Vincent, NC Survivor's Union, USA</p>	16:05 - 16:25	<p>The ethical issues of implementing safe supply in practice Marie-Eve Goyer, CIUSSS Centre-Sud-de-l'Île-de-Montréal, Canada</p>		
16:25 - 16:45	<p>Peer delivered interventions/models Brian Moore, We Are With You, UK</p>	16:25 - 16:45	<p>Drug Policy Interventions Shaun Shelly, South African Network of People Who Use Drugs (SANPUD), South Africa</p>	16:25 - 16:45	<p>Moving safer supply forward: the need for decriminalisation and demedicalised models of safe supply Matthew Bonn, Canadian Association of People Who Use Drugs (CAPUD), Canada</p>		
16:45 - 17:15	<p>Questions & Discussion</p>	16:45 - 17:15	<p>Questions & Discussion</p>	16:45 - 17:15	<p>Questions & Discussion</p>		
19:00 - 23:00	<p>Conference Dinner</p>						

09.15 - 11.00	Session T: Improving the health of people who use drugs Room: Lomond Auditorium Chairs: Dave Liddell, Scottish Drugs Forum, UK & Alison Ritter, Social Policy Research Centre, Australia
09.15 - 09.20	Overview of Jude Byrne Award Annie Madden, International Network of People who Use Drugs (INPUD), Australia
09.20 - 09.25	Reflections on the Jude Byrne Emerging Female Leader Award Yatie Jonet, Persatuan Insaf Murni Malaysia, Malaysia
09.25 - 09.30	Reflections on the Jude Byrne Emerging Female Leader Award Danielle Russell, Arizona State University, USA
09.30 - 09.50	Community-led models for improving the health of people who use drugs – Successes, challenges and where to next Magdalena Harris, London School of Hygiene and Tropical Medicine, UK
09.50 - 10.10	How do we address the broader social and health issues among people who inject drugs? Dame Carol Black, Independent Adviser on Combating Drugs Misuse, UK
10.10 - 10.30	Questions & Discussion
10.30 - 10.45	Health benefits and public order improvements after the implementation of DCRs in France. Results from the COSINUS cohort survey Marie Jauffret-Roustide, Inserm, France
10.45 - 11.00	Evaluating the impact and cost-effectiveness of a novel police education program on HIV and overdose among people who inject drugs in Tijuana, Mexico Natasha Martin, University of California, San Diego, USA

11.00 - 11.45 Coffee Break & Poster Tour

11.10 - 11.35	Poster Tour 03: Integrated Care Strategies/Models Chair: Evan Cunningham, Kirby Institute, UNSW Sydney, Australia	11.10 - 11.35	Poster Tour 04: Reducing Drug-Related Harms Chair: Adelina Artenie, University of Bristol, UK
11.10 - 11.15	Dry Blood Spot Polymerase Chain Reaction (DBS PCR) Blood Borne Virus (BBV) Testing in the setting of police custody Erica Peters, NHS Greater Glasgow and Clyde, UK	11.10 - 11.15	The impact of COVID-19 in the consumption patterns of people who inject drugs Joana Pires, Médicos Do Mundo, Portugal
11.15 - 11.20	Evaluation of a naloxone pilot among police officers in Scotland: a public health approach to policing Elizabeth Speakman, Edinburgh Napier University, UK	11.15 - 11.20	Overlapping adverse health outcomes among people who inject drugs in England, Wales and Northern Ireland, 2019-2020 Claire Edmundson, UK Health Security Agency, UK
11.20 - 11.25	Rapid Hepatitis C Treatment Initiation in Young People who Inject Drugs: Final Results From The HCV-Seek, Test & Rapid Treatment (HCV-ST&RT) Randomized Pilot Clinical Trial. Benjamin Eckhardt, NYU School of Medicine/Bellevue Hospital, USA	11.20 - 11.25	A systematic review of psychosocial factors associated with risk of drug-related overdose Amy Malaguti, NHS Tayside / University of Dundee, UK
11.25 - 11.30	Evaluation of Universal Hepatitis C Screening and Treatment among Psychiatry Inpatients Erin Mandel, University Health Network, Canada	11.25 - 11.30	Piloting a digital health respiratory monitoring intervention to reduce drug-related deaths – The 'RESCU' project Kristina Hnízdilová, University of Dundee, UK
		11.30 - 11.35	Promoting community naloxone provision; utilising people with lived experience to address Drug Related Deaths within Dundee Toni-Marie Porter, Hillcrest Futures, UK

11.45 - 12.45	Session U Oral Abstract Session: Strategies to enhance HCV testing and treatment Room: Lomond Auditorium Chairs: Mia Biondi, York University, Canada & Shashi Kapadia, Weill Cornell Medicine, USA	11.45 - 12.45	Session V Oral Abstract Session: Treatment of HCV infection among PWID Room: Alsh (A) Chairs: Phillip Bruggmann, Arud, Centre for Addiction Medicine, Switzerland & Mercy Nyakowa, Ministry of Health - National AIDS and STI Control Program, Kenya	11.45 - 12.45	Session W Oral Abstract Session: Enhancing efforts to improve HCV outcomes Room: Boisdale (B) Chairs: David Whiteley, Glasgow Caledonian University, UK	11.45 - 12.45	Session X Oral Abstract Session: Equity and Identity Room: Dochart (D) Chairs: Rachel Halford, Hep C Trust, UK & Sarah Larney, Université De Montréal, Canada
11.45 - 12.00	HepCURE™ HCV model of care – Successes and learnings from our collective efforts in screening and linkage to care activities during the COVID-19 pandemic. Christian Marcoux, HepCURE™, Canada	11.45 - 12.00	Effect of integrated treatment of Hepatitis C virus infection on treatment initiation and sustained virologic response among people who inject drugs: A multi-center randomized controlled trial (Intro-HCV) Lars T. Fadnes, Haukeland University Hospital, Norway	11.45 - 12.00	Accelerating Hepatitis C treatment initiation in people who inject drugs from remote areas via resource and network sharing among primary care centers in Malaysia Muhammad Radzi Abu Hassan, Ministry of Health, Malaysia	11.45 - 12.00	Are we leaving women who inject drugs behind on the 'road to hepatitis C elimination'? A qualitative exploration to minimise inequalities in health. Alison Marshall, The Kirby Institute, UNSW Sydney, Australia
12.00 - 12.15	Accessible HCV care for people who inject drugs: Randomized clinical trial comparing low-threshold treatment at a syringe service program versus facilitated referral. Benjamin Eckhardt, NYU School of Medicine/Bellevue Hospital, USA	12.00 - 12.15	Development of a Calgary inner-city HCV network to support Hepatitis C screening, treatment and linkage to care for priority populations Nicola Gale, Cups Liver Clinic, Canada	12.00 - 12.15	The role of adherence support in achieving HCV cure among people who inject drugs accessing harm reductions settings in Kenya Mercy Nyakowa, Ministry of Health - National AIDS and STI Control Program, Kenya	12.00 - 12.15	Unstable housing may be a major obstacle on the road to HCV elimination. Results from the treatment as prevention (TraP HepC) program in Iceland. Sigurdur Olafsson, Landspítali University Hospital, Iceland
12.15 - 12.30	Hepatitis C treatment uptake following a Hepatitis C Point-of-Care testing "Blitz" at a prison in Queensland, Australia: The Woodford Prison testing campaign Mim O'Flynn, Kombi Clinic Ltd, Australia	12.15 - 12.30	National direct acting antiviral treatment and retreatment discontinuation in Australia Joanne Carson, The Kirby Institute, UNSW Sydney, Australia	12.15 - 12.30	Changing attitudes of the general public towards people with prison and injecting drug use histories: A research-informed, co-designed, arts-based intervention Carla Treloar, UNSW, Australia	12.15 - 12.30	An adaptive approach and community-led model to enable access to treatment and cure Hepatitis C in rural and indigenous communities for people who inject drugs in Saskatchewan, Canada Stuart Skinner, Wellness Wheel, Canada
12.30 - 12.35	Implementing Community-Based Models of Hepatitis C Care to Achieve Elimination: The Tasmanian Eliminate Hepatitis C Australian Outreach Project Megan Hughes, Burnet Institute, Australia	12.30 - 12.35	HCV treatment uptake among people who inject drugs in Oslo: A registry-based study Kristian Malm, Akershus University Hospital, Norway	12.30 - 12.35	Community-based HCV therapy with Sofosbuvir and Velpatasvir in the inner city Brian Conway, Vancouver Infectious Diseases Centre, Canada	12.30 - 12.35	Factors associated with Hepatitis C virus treatment uptake among females with drug dependence in the direct acting antiviral era in New South Wales, Australia Heather Valerio, The Kirby Institute, Australia
12.35 - 12.40	Meeting people where they are at: Preliminary results from the evaluation of HEP@HOME, a mobile outreach program targeting people who inject drugs and who have reduced access to mainstream Hepatitis C (HCV) health services Phillip Read, Kirketon Road Centre, Australia	12.35 - 12.40	Non-uptake of treatment for Hepatitis C in the antiviral era: A qualitative analysis Suzanne Fraser, Australian Research Centre In Sex, Health And Society, La Trobe University, Australia	12.35 - 12.40	End Hep C SF and the power of collective impact Katie Burk, Facente Consulting, USA	12.35 - 12.40	"Protective, Private, Proud": Identity matters for gay and bisexual men who inject drugs in Australia Sophia E Schroeder, Burnet Institute, Australia
		12.40 - 12.45	Evaluating the cost-effectiveness of integrated treatment for Hepatitis C virus among people who inject drugs in Norway Aaron G Lim, University Of Bristol, UK	12.40 - 12.45	Wessex Clinical Vans Louise Hansford, Inclusion, UK		

12.45 - 14.30 Lunch

13.15 - 14.00	Designing focused, tailored and prioritized HIV and viral hepatitis interventions for people who use drugs Room: Lomond Auditorium Chair: Monica Ciupagea, United Nations Office on Drugs and Crime (UNODC), Austria	13.15 - 14.15	INHSU Prisons regional spotlights (UK, EU, and Asia): Harm reduction and Hepatitis C in correctional settings Room: Alsh (A) Chairs: Joaquin Cabezas, Marques de Valdecilla University Hospital, Santander, Spain & Nadine Kronfli, McGill University Health Centre, Canada	13.15 - 14.15	Nurses Fireside Chats Room: Boisdale (B) Chairs: Mia Biondi, York University, Canada	13.15 - 14.15	From Test to Cure: Love, Harm Reduction, and Human Connection as the Lifeblood of Hepatitis C Elimination (60-minute Workshop) Room: Dochart (D) Chair: Andy Seaman, Central City Concern, USA Co-facilitators: Leanne Falzon, Ian Alexander, Sky Liepold, Central City Concern, USA
13.15 - 13.20	Introduction and moderation Monica Ciupagea, United Nations Office on Drugs and Crime (UNODC), Austria	13.15 - 13.30	Best practice strategies for implementing and scaling up harm reduction services in correctional settings in Moldova Svetlana Doltu, NGO AFI, Republic of Moldova	13.15 - 13.20	Welcome and Introduction Mia Biondi, York University, Canada	13.15 - 14.05	Workshop This workshop from the Central City Concern Hep C Elimination program, which links > 90% of a vulnerable population living with homelessness and active chaotic drug use, focuses on the human relational components of HCV care critical for elimination. They invite delegates to explore the ways their local systems could become more interconnected and interdependent to identify, re-engage, support, and inspire those living with HCV toward treatment.
13.20 - 13.30	Community perspective on access to harm reduction Judy Chang, International Network of People Who Use Drugs (INPUD), Italy	13.30 - 13.45	Enhancing hepatitis C testing and treatment in correctional settings in the UK: advances and remaining challenges Iain Brew, Health in Justice, UK	13.20 - 13.40	Nurse-led HIV prevention – clinical aspects and mobilization of community organisations and pharmacists Mia Biondi, York University, Canada		
13.30 - 13.40	Documenting Egypt's adoption and upcoming rollout of OAT Amdad ElZahaby, HIV Scientific Committee, Egypt; and Menan Abdel Maksoud, Ministry of Health and Population, Egypt	13.45 - 14.00	Initiatives to improve HCV testing, linkage to care and treatment in correctional settings in Iran Maryam Alavi, The Kirby Institute, UNSW Sydney, Australia	13.40 - 14.00	Nurse-led models of hepatitis care: In-reach model in Australian prisons Anne Craigie, St Vincent's Hospital, Melbourne, Australia		Delegates will explore the ways they do or could break down boundary dogma to incorporate explicit recognition of love as a core requirement for liberation medicine as a pathway to hepatitis C care at an individual and population level. They will also explore the extension of the philosophies of harm reduction into all interactions with those we serve, our teams, and health systems.
13.40 - 13.50	Introducing the WHO consolidated guidelines for key populations Niklas Luhmann, World Health Organization, Switzerland	14.00 - 14.15	Questions & Discussion	14.00 - 14.15	Wrap up and Networking Mia Biondi, York University, Canada	14.05 - 14.15	Session Wrap, Integration, and Next Steps
13.50 - 14.00	Introducing the UNODC-WHO OAT Operational tool and training package Monica Ciupagea, United Nations Office on Drugs and Crime (UNODC), Austria						

14.30 - 16.00	<p>Session Y: How can we improve global coverage of interventions to reduce drug-related harms? Room: Lomond Auditorium</p> <p>Chairs: Julie Bruneau, Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Canada & Matt Hickman, University of Bristol, UK</p>	14.30 - 16.00	<p>Session Z: Meeting the needs of people who use drugs Room: Alsh (A)</p> <p>Chairs: Hannah Carver, University of Stirling, UK & Stuart Skinner, Wellness Wheel/University Of Saskatchewan, Canada</p>	14.30 - 16.00	<p>Session ZA: New Innovations to Control HIV Transmission Among PWID Room: Boisdale (B)</p> <p>Chairs: Erica Peters, Queen Elizabeth University Hospital, UK</p>	14.30 - 16.00	<p>Session ZB: C-EHRN - Boosting communities and increasing impact: the need for scaling up community-based HCV prevention, treatment and linkage to care services for PWUD Room: Dochart (D)</p>
14.30 - 14.45	<p>Global epidemiology of injecting drug use, HIV, HCV, and harm reduction coverage Louisa Degenhardt, National Drug and Alcohol Research Centre, Australia</p>	14.30 - 14.50	<p>The critical role of gender-responsive services to meet the needs of people who use drugs Rose Schmidt, University of Toronto, Canada</p>	14.30 - 14.50	<p>Approaches to tackling recent HIV outbreaks Vana Sypsa, National And Kapodistrian University Of Athens, Greece</p>	14.30 - 14.35	<p>BOOST. Upscaling community-based communicable diseases services in Europe Roberto Perez Gayo, Correlation – European Harm Reduction Network, Netherlands</p>
14.45 - 15.00	<p>Successful models for implementation of harm reduction programmes Monica Ciupagea, United Nations Office on Drugs and Crime (UNODC), Austria</p>	14.50 - 15.10	<p>Homelessness & Mental Health Tessa Parkes, University Of Stirling, UK</p>	14.50 - 15.10	<p>Recent advances in therapeutic approaches to prevent and treat HIV among PWID Becky Metcalfe, Glasgow Caledonian University, UK</p>	14.35 - 14.45	<p>Community-based approaches to non-communicable diseases in Belgium Tessa Windelinckx, Free Clinic, Belgium</p>
15.00 - 15.15	<p>How can we improve data and mobilise funding for harm reduction support globally? Keith Sabin, UNAIDS, Switzerland</p>	15.10 - 15.30	<p>Peer-delivered interventions Aura Roig Forteza, Metzineres, Spain</p>	15.10 - 15.30	<p>What will it take to reach and sustain control of HIV among PWID? Brandon Marshall, Brown University, USA</p>	14.45 - 14.55	<p>Community-based approaches to non-communicable diseases in Czech Republic Lucie Maskova, Spolecnost Podane Ruce, Czech Republic</p>
15.15 - 15.30	<p>How can we use advocacy and community-led monitoring to improve coverage and quality of services to reduce drug-related harms? Judy Chang, International Network of People Who Use Drugs (INPUD), Italy</p>	15.30 - 16.00	<p>Questions & Discussion</p>	15.30 - 16.00	<p>Questions & Discussion</p>	14.55 - 15.05	<p>Community-based approaches to non-communicable diseases in Finland Jukka Koskela, A-Clinic Foundation, Finland</p>
15.30 - 16.00	<p>Questions & Discussion</p>					15.05 - 15.15	<p>Community-based approaches to non-communicable diseases in Italy Nadia Gasbarrini, Fondazione Villa Maraini, Italy</p>
						15.15 - 15.55	<p>Group Discussion</p>
						15.55 - 16.00	<p>Conclusions</p>
16.00 - 16.20	Coffee Break						
16.20 - 17.30	<p>Conference Closing Room: Lomond Auditorium Chairs: Jason Grebely, The Kirby Institute, UNSW Sydney, Australia & Sharon Hutchinson, Public Health Scotland & Glasgow Caledonian University, UK</p>						
16.20 - 16.25	INHSU Early-Mid-Career Researchers & Community Collaborations – Report Back						
16.25 - 16.35	<p>Community Rapporteur KerryAnn Colquhoun, Turning Point, UK</p>						
16.35 - 16.45	<p>Epidemiology & Public Health Rapporteur Sofia Bartlett, BC Centre for Disease Control, Clinical Prevention Services, Canada</p>						
16.45 - 16.55	<p>Clinical Science Rapporteur Thomas Brothers, Dalhousie University & University College London, Canada</p>						
16.55 - 17.05	<p>Models of Care Rapporteur Brendan Harney, Burnet Institute, Australia</p>						
17.05 - 17.15	<p>Social Science & Policy Rapporteur David Whiteley, Glasgow Caledonian University, UK</p>						
17.15 - 17.25	<p>Conference Closing Jason Grebely, The Kirby Institute, UNSW Sydney, Australia & Sharon Hutchinson, Public Health Scotland & Glasgow Caledonian University, UK</p>						
17.25 - 17.30	Announcement of 2023 Conference						